← Back

PathMaker Neurosystems Receives the Innovation Prize 2016

Boston, Massachusetts and Paris, France (October 4, 2016) — PathMaker Neurosystems (“PathMaker”), a clinical-stage neurotechnology company developing non-invasive neurotherapy systems for the treatment of patients with neuromotor disorders, has been named as the Recipient of the Universal Biotech Innovation Prize 2016 in the global competition that offers “a glimpse of the future of life sciences.”

The Innovation Prize awards were announced following presentations during Innovation Days, an international event gathering leading companies and researchers in the Life Sciences field, held October 3-4, 2016, at the Maison de la Chimie in Paris, France.

PathMaker Neurosystems named as the recipient of the Universal Biotech Innovation Prize 2016.
PathMaker Neurosystems named as the recipient of the Universal Biotech Innovation Prize 2016.

“At PathMaker, we are tremendously honored and excited to have been awarded the Innovation Prize 2016,” said Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer of PathMaker. “This prestigious prize reflects not only the rapid progress our expert team has made in translating fundamental discoveries into novel therapeutic devices, but the human impact our non-invasive technology will have for patients with paralysis, muscle weakness and spasticity.”

The international competition, started in 2009 by Universal Biotech and now in its eighth year, honors the world’s most innovative startups and the best academic research groups that are “developing cutting edge technologies in the field of life sciences.” Of the 259 entrants from 38 countries this year, PathMaker was selected after four evaluation rounds as Innovation Prize 2016 Laureate, with awards given out in both the MedTech and Biotech categories.  Companies were analyzed according to scientific quality of the innovation, intellectual property, quality of the human resources, project feasibility and market access strategy.  The entrants included applications from the Biotech, Medtech, e-health and diagnostics segments of the life sciences field.  The jury included leading and prominent experts from major healthcare companies, pharmaceutical companies, biotechnology societies, and legal firms with extensive experience reviewing novel technologies. More information is available here.

PathMaker is developing breakthrough non-invasive systems that treat patients suffering from neural pathway disruptions such as stroke, cerebral palsy, multiple sclerosis, Parkinson’s disease, traumatic brain injury and spinal cord injury. There are more than 48 million affected patients in the U.S., Europe, and China alone with these conditions.  PathMaker’s first product, MyoRegulator™, provides a breakthrough non-invasive treatment for muscle spasticity and is now in IRB-approved human clinical trials.  The company’s second product, MyoAmplifier™, provides an advanced non-invasive platform that treats paralysis and muscle weakness.

About PathMaker Neurosystems Inc.

PathMaker Neurosystems is a clinical-stage neuromodulation company developing breakthrough non-invasive systems for the treatment of patients with chronic neuromotor conditions. With offices in Boston (US) and Paris (France), PathMaker is moving forward a trans-Atlantic strategy to rapidly bring to market entirely novel, breakthrough approaches to non-invasively treating neuromotor disorders. More than 48 million patients in the US, Europe and China suffer disabilities due to stroke, cerebral palsy, multiple sclerosis, spinal cord injury, traumatic brain injury, Parkinson’s disease and other neurological disorders. At PathMaker, we are opening up a new era of non-invasive neurotherapy for patients suffering from chronic neuromotor conditions. Visit the company website at www.pmneuro.com.